Home
Search
Study Topics
Glossary
|
|
|
|
|
Tracking Information | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
First Received Date † | July 2, 2007 | ||||||||||||
Last Updated Date | January 27, 2009 | ||||||||||||
Start Date † | October 2007 | ||||||||||||
Current Primary Outcome Measures † |
Cure rate [ Time Frame: Day 9-11 ] [ Designated as safety issue: Yes ] | ||||||||||||
Original Primary Outcome Measures † | Same as current | ||||||||||||
Change History | Complete list of historical versions of study NCT00495586 on ClinicalTrials.gov Archive Site | ||||||||||||
Current Secondary Outcome Measures † |
Number of days till the next exacerbation [ Time Frame: One year ] [ Designated as safety issue: Yes ] | ||||||||||||
Original Secondary Outcome Measures † | Same as current | ||||||||||||
Descriptive Information | |||||||||||||
Brief Title † | Effectiveness of Antibiotic Therapy for Exacerbations of Chronic Obstructive Pulmonary Disease | ||||||||||||
Official Title † | Situations That do Not Require Antibiotics for Acute Exacerbations of Mild-to-Moderate Chronic Obstructive Pulmonary Disease | ||||||||||||
Brief Summary | The purpose of this study is to determine the effectiveness of antibiotic therapy for patients with acute exacerbations of mild-to-moderate chronic obstructive pulmonary disease. |
||||||||||||
Detailed Description | Antibiotics are usually prescribed for acute exacerbations of chronic obstructive pulmonary disease (COPD) even though their benefit in mild-to-moderate COPD is not demonstrated. The aim of this study is to assess the effectiveness of antibiotic therapy for exacerbations of COPD, what clinical variables are associated with an improved clinical response with antibiotic therapy with respect to placebo and to identify which patients might recover from an acute exacerbation without antibiotic therapy. Methodology: prospective, randomised, double blind, placebo-controlled clinical trial, in which exacerbations (at least one criterion present: increase of dyspnoea, increase of sputum production and/or increase of purulence) of patients older than 40 yr., smokers or ex-smokers of more than 10 pack-years, with COPD and FEV1 greater than 50%, diagnosed by spirometry and a predicted ratio FEV1/FVC<0.7%. Exclusion criteria: severe COPD (FEV1<50%), active neoplasm, tracheotomy, pneumonia, hospitalization criteria, patients previously being on antibiotics, immunodepressed, history of hypersensitivity to beta-lactams or intolerance to clavulanate, enrollment in other clinical trials, patients who refuse to take part in this study, and patients who have not had a spirometry test for the past two years. Sample size: 677 patients. Interventions: first visit: the patient will be given details of the clinical trial and will be asked to sign informed consent; other data: sputum color, chest X-ray ordered to rule out pneumonia, C-reactive protein levels, and peak flow measurement. The patient will be randomised to receive amoxicillin plus clavulanate or placebo and will be scheduled to return for a 2nd follow-up visit after 3 or 4 days to assess the clinical response and peak flow measurements and to rule out any worsening of the condition. Third visit: scheduled after 9-11 days to assess the clinical response, drug-compliance and peak flow measurement. Fourth visit after 15-20 days for clinical assessment and to observe whether any relapses have occurred. Date of the following exacerbation will be recorded. |
||||||||||||
Study Phase | Phase IV | ||||||||||||
Study Type † | Interventional | ||||||||||||
Study Design † | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study | ||||||||||||
Condition † | Chronic Obstructive Pulmonary Disease | ||||||||||||
Intervention † |
|
||||||||||||
Study Arms / Comparison Groups |
|
||||||||||||
Publications * | |||||||||||||
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|||||||||||||
Recruitment Information | |||||||||||||
Recruitment Status † | Recruiting | ||||||||||||
Enrollment † | 677 | ||||||||||||
Estimated Completion Date | March 2010 | ||||||||||||
Primary Completion Date | November 2007 (final data collection date for primary outcome measure) | ||||||||||||
Eligibility Criteria † | Inclusion Criteria:
Exclusion Criteria:
|
||||||||||||
Gender | Both | ||||||||||||
Ages | 40 Years and older | ||||||||||||
Accepts Healthy Volunteers | No | ||||||||||||
Contacts †† |
|
||||||||||||
Location Countries † | Spain | ||||||||||||
Expanded Access Status | |||||||||||||
Administrative Information | |||||||||||||
NCT ID † | NCT00495586 | ||||||||||||
Responsible Party | Ramon Morera, Catalan Institute of Health | ||||||||||||
Secondary IDs †† | |||||||||||||
Study Sponsor † | Catalan Society of Family Medicine | ||||||||||||
Collaborators †† | Fondo de Investigacion Sanitaria | ||||||||||||
Investigators † |
|
||||||||||||
Information Provided By | Catalan Society of Family Medicine | ||||||||||||
Verification Date | January 2009 | ||||||||||||
† Required WHO trial registration data element. †† WHO trial registration data element that is required only if it exists. |